Nutriband Inc.
NASDAQ:NTRBBiotechnology
+$0.85 today
- Market cap
- $67.95M
- Beta
- 1.97
- P/E (TTM)
- -1.8
- EPS (TTM)
- -$0.66
Volume 0.02M
Average 0.01M
NTRB Operating Margin
Operating income as a percentage of revenue, showing the profitability of core operations.
Nutriband Inc.NASDAQ: NTRB
Operating Margin · Q1 FY2026 · quarter ended Apr 2026
Operating margin narrows to -289.4%
Operating margin was -289.4% in Q1 FY2026, down 77.6 pp from a year earlier. On a trailing-twelve-month basis it was -452.6%, down 193.5 pp year over year. Over 3 fiscal years it narrowed by 209.0 pp.
Context
- Operating margin widened in 0 of the last 3 fiscal years.
- FY2025 was the lowest level in the 4 fiscal years shown.
What to watch
Whether operating margin reaches the consensus estimate from 1 analysts of 24.3% for the fiscal year ending Jan 2027, up from -408.4% in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterApr 2026
- -289.4%-34.6 pp QoQ
- Last fiscal yearJan 2026
- -408.4%-95.8 pp YoY
- LTMApr 2026
- -452.6%-193.5 pp YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | -77.6 pp | — | — |
| 1 year | -95.8 pp | +432.7 pp | +528.5 pp |
| 3 years | -209.0 pp | — | — |
| 5 years | — | — | |
| 10 years | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Operating Margin history
Percent of revenue · from the income statement
- Latest · FY2025
- -408.4%
- Year-over-year change
- -95.8pp
| Period | Period end | Operating Margin | YoY change |
|---|---|---|---|
| FY2025 | 2026-01-31 | -408.4% | -95.8pp |
| FY2024 | 2025-01-31 | -312.6% | -79.0pp |
| FY2023 | 2024-01-31 | -233.6% | -34.2pp |
| FY2022 | 2023-01-31 | -199.5% | +76.9pp |
| FY2021 | 2022-01-31 | -276.3% | — |
Operating Margin vs competitors
How NTRB compares with its peers on the latest reported figures
- NTRB's LTM Apr 2026 operating margin of -452.6% is the 2nd highest of the 4 companies compared; the peer median is -1408.7%.
- Its year-over-year change of -193.5 pp is the lowest of 3, against a peer median of +919.5 pp.
- Over three fiscal years its change of -209.0 pp compares with a peer median of +157.8 pp.
| Company | Period | LTM level | YoY | 3-year change |
|---|---|---|---|---|
| LTM Mar 2026 | -84.4% | +87.9 pp | +157.8 pp | |
| LTM Apr 2026 | -452.6% | -193.5 pp | -209.0 pp | |
| LTM Mar 2026 | -1408.7% | +1751.1 pp | -823.1 pp | |
| LTM Jun 2024 | -4534.8% | — | +623.6 pp | |
| FY2025 | — | — | — | |
ACRVAcrivon Therapeutics, Inc. Common Stock | FY2025 | — | — | — |
| FY2025 | — | — | — | |
| FY2025 | — | — | — | |
| FY2025 | — | — | — | |
| Peer median (excluding NTRB) | -1408.7% | +919.5 pp | +157.8 pp | |
Competitors are the stored peer set for NTRB. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Jan 2022 | FY2022 Jan 2023 | FY2023 Jan 2024 | FY2024 Jan 2025 | FY2025 Jan 2026 |
|---|---|---|---|---|---|
| Revenue | 1.42M | 2.08M | 2.09M | 2.14M | 2.04M |
| Cost of Revenue | 917.84K | 1.33M | 1.22M | 1.44M | 1.47M |
| Gross Profit | 504.31K | 750.41K | 862.11K | 699.3K | 566.31K |
| Gross Margin | 35.5% | 36.1% | 41.3% | 32.7% | 27.8% |
| Research & Development | 411.38K | 982.23K | 1.96M | 3.12M | 1.89M |
| Selling, General & Admin | 4.02M | 3.92M | 3.77M | 4.27M | 6.99M |
| Operating Expenses | 4.43M | 4.9M | 5.73M | 7.39M | 8.88M |
| Depreciation & Amortization | 318.26K | 368.96K | 287.72K | 285.05K | 193.8K |
| EBITDA | (5.74M) | (4.11M) | (5.12M) | (10.18M) | (8.01M) |
| EBITDA Margin | -403.6% | -197.5% | -245.6% | -475.5% | -393.5% |
| Operating Income | (3.93M) | (4.15M) | (4.87M) | (6.69M) | (8.32M) |
| Operating Margin | -276.3% | -199.5% | -233.6% | -312.6% | -408.4% |
| Interest Income | 0 | 0 | 16.85K | 191.67K | 0 |
| Interest Expense | 118.42K | 8.29K | 75.82K | 21.41K | 22.54K |
| Other Income / Expenses | (2.25M) | (335.62K) | (613.39K) | (3.79M) | 88.33K |
| Income Before Tax | (6.18M) | (4.48M) | (5.49M) | (10.48M) | (8.23M) |
| Pre-Tax Margin | -434.3% | -215.6% | -263.0% | -489.9% | -404.1% |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (8.42M) | (4.81M) | (5.49M) | (10.48M) | (8.23M) |
| Net Margin | -592.2% | -231.3% | -263.0% | -489.9% | -404.1% |
| EPS (Basic) | (1.06) | (0.57) | (0.69) | (0.99) | (2.58) |
| EPS (Diluted) | (1.06) | (0.57) | (0.69) | (0.99) | (2.58) |
| Weighted Avg Shares | 7.93M | 8.46M | 7.95M | 10.61M | 11.64M |
| Weighted Avg Shares (Diluted) | 7.93M | 8.46M | 7.95M | 10.61M | 11.64M |
Nutriband Inc.
NASDAQ:NTRB
Intrinsic Alpha fair value
Locked
Current Price
$5.59
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.